Tag: Antiviral resistance

Globally, antimicrobial resistance (AMR), which includes antiviral resistance, was directly responsible for an estimated 1.27 million deaths in 2019 [1.6.3]. This guide explores the full spectrum of what the risks of antivirals are, from common side effects to long-term implications.

Skipping doses or stopping antiviral medication prematurely can lead to a serious phenomenon known as antiviral resistance, where the virus mutates and the medication becomes ineffective. Understanding why is it bad to stop antivirals early is crucial for effective treatment and long-term health.

Affecting a significant portion of the population, herpes simplex virus (HSV) is typically managed effectively with antiviral medications like valacyclovir. However, a frustrating and concerning question arises when a once-effective treatment fails: why is valacyclovir not working anymore? This article explores the various reasons for treatment failure, including viral resistance and patient-specific factors, and discusses management strategies.

In a study of HIV patients, viral load rebounded within days of stopping antiretroviral therapy, even after long-term suppression. This illustrates the serious and rapid consequences of stopping antivirals early, which can lead to viral resurgence and the development of drug resistance.

In clinical trials, a single dose of baloxavir marboxil led to a significantly more rapid and potent reduction in viral load within 24 hours compared to both placebo and oseltamivir. This distinctive action offers a new approach to influenza treatment and prevention.

Each year, millions of people in the U.S. get sick with the seasonal flu [1.7.3]. While antiviral drugs exist, you might wonder, **Why don't doctors prescribe antivirals** for every sniffle? The answer involves a careful balance of efficacy, risks, and public health.

Globally, an estimated 3.8 billion people under age 50 (64%) have herpes simplex virus type 1 (HSV-1). A common question for those on long-term treatment is: **do you build a tolerance to valacyclovir**, the antiviral medication used to manage it?

While exceedingly rare in immunocompetent individuals (prevalence generally below 1%), acyclovir resistance in herpes simplex virus (HSV) is a well-documented and growing concern, especially among immunocompromised populations. The emergence of these drug-resistant strains poses significant clinical challenges for managing chronic and severe HSV infections.